Open-label extension and post-hoc analyses add to the evidence base for clinical and endoscopic outcomes with risankizumab and upadacitinib. Risankizumab in UC: COMMAND showed sustained clinical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results